Product Description
OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15242254/)
Mechanisms of Action: cGAMP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer|Melanoma|Lymphocytic Chronic B-Cell Leukemia|Renal Cell Carcinoma|Crohn Disease|Chronic Lymphoid Leukemia
Phase 1: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00036257 |
OSI-461-010 | P1 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
None |
2019-03-21 |
||
NCT00036075 |
OSI-461-006 | P2 |
Completed |
Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00060710 |
OSI-461-013 | P2 |
Terminated |
Melanoma |
None |
2019-03-21 |
Treatments |
|
NCT00073489 |
OSI-461-005 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
None |
2019-03-21 |
||
NCT00036036 |
OSI-461-003 | P2 |
Completed |
Renal Cell Carcinoma |
None |
2019-03-21 |
||
NCT00042055 |
OSI-461-012 | P2 |
Completed |
Crohn Disease |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|